The immunotherapy agent nivolumab, which inhibits the PD-1/PD-L1 interaction, has recently proven effective in treating non-small cell lung cancer (NSCLC), reducing the risk of death compared to standard chemotherapy regimens [11]. Here, CD274 is linked to non-small cell lung carcinoma.